These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 21868783)
21. Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial. van Raalte DH; Bunck MC; Smits MM; Hoekstra T; Cornér A; Diamant M; Eliasson B; Marja-RiittaTaskinen ; Heine RJ; Smith U; HanneleYki-Järvinen ; Mari A Eur J Endocrinol; 2016 Oct; 175(4):345-52. PubMed ID: 27466218 [TBL] [Abstract][Full Text] [Related]
23. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Tushuizen ME; Bunck MC; Pouwels PJ; van Waesberghe JH; Diamant M; Heine RJ Liver Int; 2006 Oct; 26(8):1015-7. PubMed ID: 16953843 [TBL] [Abstract][Full Text] [Related]
24. [GLP-1-based treatment of type 2 diabetes mellitus]. Knop FK; Vilsbøll T Ugeskr Laeger; 2007 May; 169(22):2095-9. PubMed ID: 17553390 [TBL] [Abstract][Full Text] [Related]
25. The effects of glucagon-like peptide-1 on the beta cell. Vilsbøll T Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257 [TBL] [Abstract][Full Text] [Related]
26. [Clinical application of exenatide in Japanese patients with type 2 diabetes mellitus]. Toyonaga T; Araki E Nihon Rinsho; 2011 May; 69(5):890-4. PubMed ID: 21595277 [TBL] [Abstract][Full Text] [Related]
27. Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide. Doggrell SA Rev Recent Clin Trials; 2007 Jan; 2(1):77-84. PubMed ID: 18473991 [TBL] [Abstract][Full Text] [Related]
28. Choosing among the incretin agents and why it matters. Unger J J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056 [No Abstract] [Full Text] [Related]
29. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary. Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106 [TBL] [Abstract][Full Text] [Related]
30. [New drugs; exenatide and sitagliptin]. van Bronswijk H; Dubois EA; Pijl H; Cohen AF Ned Tijdschr Geneeskd; 2008 Apr; 152(15):876-9. PubMed ID: 18512528 [TBL] [Abstract][Full Text] [Related]
31. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes. Painter NA; Morello CM; Singh RF; McBane SE J Am Board Fam Med; 2013; 26(2):203-10. PubMed ID: 23471935 [TBL] [Abstract][Full Text] [Related]
32. [The value of incretin based therapies]. Gallwitz B Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931 [No Abstract] [Full Text] [Related]
33. Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. Wajcberg E; Tavaria A Expert Opin Pharmacother; 2009 Jan; 10(1):135-42. PubMed ID: 19236187 [TBL] [Abstract][Full Text] [Related]
35. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Davies M; Heller S; Sreenan S; Sapin H; Adetunji O; Tahbaz A; Vora J Diabetes Care; 2013 May; 36(5):1368-76. PubMed ID: 23275363 [TBL] [Abstract][Full Text] [Related]
36. [Exenatide--an alternative to insulin in the treatment of type 2 diabetes?]. Kjeldsen R; Sandbaek A Ugeskr Laeger; 2008 Sep; 170(39):3039-43. PubMed ID: 18822227 [TBL] [Abstract][Full Text] [Related]
37. Drugs for diabetes. Abramowicz M; Zuccotti G; Treat Guidel Med Lett; 2005 Aug; 3(36):57-62. PubMed ID: 16012392 [No Abstract] [Full Text] [Related]
38. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus. Hoogwerf BJ Cleve Clin J Med; 2006 May; 73(5):477-84. PubMed ID: 16708716 [TBL] [Abstract][Full Text] [Related]